Recent Post
Related Posts
IGC PHARMA Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
Both the primary and secondary objectives aim to evaluate the efficacy of IGC-AD1 in reducing agitation as assessed by the CMAI at week 2 and week 6 respectively.
Parkinson’s awareness month
____________________________
Parkinson’s disease psychosis is a neuropsychiatric complication that affects more than 20% of patients affected by Parkinson’s. Common
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer’s Research
By: Faith Ashmore Benzinga Staff Writer As of 2023, the estimated number of Americans living with Alzheimer’s disease was 6.7 million. However, a lesser-known subsection of Alzheimer’s is Agitation in dementia from
By: Faith Ashmore Benzinga Staff Writer Alzheimer’s disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline and behavioral changes. The impact
Synesthesia is a complex experience that involves perceiving the elements of the world with more than one sense. By integrating the knowledge of neuroscience with these aspects of perception, scientists
COMPANY
